Dual antiplatelet therapy noninferior to alteplase in minor stroke

In the randomized ARAMIS trial involving 719 patients with minor nondisabling acute ischemic stroke presenting within 4.5 hours of symptom onset, the rate of excellent functional outcome at 90 days was 93.8% in the dual antiplatelet therapy (DAPT; clopidogrel plus aspirin) group vs. 91.4% in the IV alteplase group, confirming noninferiority of DAPT.